CARE Carecapital

TIDMAVO

RNS Number : 7074Z

Advanced Oncotherapy PLC

21 September 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Notice of results

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, will announce its interim results for the six months ended 30 June 2015 tomorrow, Tuesday 22 September 2015.

 
  Advanced Oncotherapy Plc                                          www.avoplc.com 
  Sanjeev Pandya, CEO                                        Tel: +44 20 3617 8728 
  Nicolas Serandour, CFO 
 
  Westhouse Securities (Nomad & 
   Joint Broker) 
  Antonio Bossi / David Coaten                               Tel: +44 20 7601 6100 
 
  Beaufort Securities (Joint Broker) 
  Jon Levinson / Elliot Hance                                Tel: +44 20 7382 8300 
 
  Walbrook PR (Financial PR & IR)      Tel: +44 20 7933 8780 or avo@walbrookpr.com 
  Paul McManus / Anna Dunphy                      Mob: +44 7980 541 893 / Mob: +44 
                                                                      7876 741 001 
 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORFMGZLDMGGKZM

(END) Dow Jones Newswires

September 21, 2015 10:31 ET (14:31 GMT)

Carecapital (LSE:CARE)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

Carecapital (LSE:CARE)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024